Section Arrow
Quote
MDGL.NASDAQ
- Madrigal Pharmaceuticals
Quotes are at least 15-min delayed:2026/01/09 09:58 EST
Regular Hours
Last
 540
-16.22 (-2.92%)
Day High 
555.1 
Prev. Close
556.22 
1-M High
615 
Volume 
134.65K 
Bid
535.2
Ask
540.05
Day Low
532.52 
Open
554.99 
1-M Low
532.445 
Market Cap 
12.63B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 581.49 
20-SMA 575.6 
50-SMA 545.7 
52-W High 615 
52-W Low 265 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.91/15.19
Enterprise Value
12.75B
Balance Sheet
Book Value Per Share
27.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
180.13M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IBIOiBio2.615+0.265+11.28%0.65PE
SLSSELLAS Life Sciences Group3.3355-0.5245-13.59%-- 
ASBPAspire Biopharma Holdings Inc.0.0992-0.0041-3.97%-- 
ARDXArdelyx7.66+0.66+9.43%-- 
MREOMereo BioPharma Group plc0.4119+0.0275+7.15%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.